Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Patients ignorant of the superiority of Vascepa are buying either gV, which is slightly cheaper than Vascepa....or Lovaza, which is much cheaper than both V or gV...so gV competition is more with Lovaza than with Vascepa.
If your main focus is the price, rather than your health, then you buy Lovaza...Europe deserves credit for taking Lovaza off the market, while Lovaza is still unaccountably outselling Vascepa in the U.S.
Amarin has never, to date, adequately explained to the public why they are wasting their money on Lovaza.
The generics may or may not be identical to each other...But they are NOT identical to Vascepa, which has a patented gelatin capsule preventing the oxidization of the vital pure EPA .
The more generics competing with Vascepa, the better...This will minimize their ill-gotten gains and make more of them susceptible to become defendants in infringement lawsuits.
Let's assume that Denner calls PFE and says let's talk...and PFE replies,fine...you send some of your people and we'll send some of ours and let's have lunch tomorrow.
Do you really expect Denner to make that interchange public?
duke...This is a VERY unusual case....This case deals with a fraud on the court...in which a document, submitted to the court, was CROPPED...in order to present exactly the WRONG factual conclusion to the court...a conclusion, which instrumental in the court's final decision.
cbd...BP continues to waste billions of dollars on the false premise that Alzheimers is due to amyloid deposits...Alzheimers is due to inflammation of the brain....Deposits of amyloid are the RESULT of inflammation of the brain...NOT THE CAUSE!.
By the time amyloid develops. it is already late in the game.This isn't to say that Vascepa, which has been proven safe and effective for CVD, can't also be of help in slowing the progress of this terrible disease!
The study (by Lilly) examined solanezumab in patients with amyloid plaque but no clinical Alzheimer's symptoms.
QUOTE from Lilly.."The A4 Study concludes our clinical development of solanezumab and indicates that targeting soluble amyloid beta through this mechanism is not effective in this population," said John Sims, Eli Lilly (NYSE:LLY) head of medical, global brand development "
This is where Vascepa,with its proven anti-inflammatory properties, can play a role!
KM might be the best executive to manage Vaskepa in Europe, but he has little or no experience in the U.S....KM has done as good a job in Europe as anyone could...Now Amarin needs to find to find a very experienced executive to manage Vascepa in the U.S....as KM frequently says..."The U.S. and Europe are very different markets"
IMO someone with a great deal of successful past experience in marketing in the U.S. and in dealing with the FDA is needed to lead Amarin's efforts in the U.S.
This is another reason for a BP to acquire Amarin.
J....You left out that dry eyes go away.
If you have a family member or a friend with AD, you come to know how debilitating it can be...IMO a positive result from Brave would spur the FDA to give approval to a safe and relatively inexpensive drug like Vascepa for the treatment of AD while larger studies are being performed.
Vascepa won't cure AD but it will be effective in slowing it's onset and its devastating results.
J.T.' problem was that he didn't fully grasp how things had changed after the judge Du decision...PWO's problem was that, even though he now knew that things had changed, he thought he could successfully proceed with what was essentially J.T.'s plan.
A new plan was needed and that is why it became necessary for Denner to come in...Vascepa is still a great drug, but it needs to be successfully managed.
For those, who are still wondering about the status of KM...QUOTE..."With the seven gone, it leaves eight people on the board of directors — seven individuals Sarissa nominated and CEO Karim Mikhail. Denner did not take a board position."
National Health Services in Europe look more at the long term than the the insurance companies in the U.S., which see a frequent turnover in their customers, leading them to be more focused on short term profits.
Europe is currently facing a cash crunch...When this situation subsides, Europe will be more on board with saving money by promoting patient's health for the long term.
dogn... PWO instituted these egregious policies as COB...Not the soldiers at the BOD
From the Nasdaq site, there have been ZERO trades over 10,000 shares after hours today and only one trade for 9500 shares...This implies all retail investors' trades....The big guns are silent.
KIWI...Vascepa is a drug that potentially every adult could/should be taking...insurance companies and national health services just don't want to pay the freight.
One way or another, it will come down in price and then usage of Vascepa will explode.
Two advantageous events today...
-Denner now can pick whom he feels is most important for his management strategies.
-The world will know that the MOM BS is put to rest for good.
IMHO, W.S. will recognize these advantages to Amarin and to Vascepa in due time.
Denner was going to decide to let some of the present BOD go, but not all....This would have been an embarrassment for those fired...The BOD members did the right thing by leaving Denner to choose whom he wanted to stay without embarrassing anyone.
The MO BS of Dr. Nissen is now in the dumpster for good
This was a proxy fight between PWO and Denner...KM was just a good soldier in this fight.
There was a risk in Amarin's policy to GIA and a risk now as well... If a BP were willing to assume that risk and pay $10/share now, I believe the offer would be accepted by Denner...However , with Amarin's current share price so low, the shareholders of the acquiring BP would be critical of the deal.
This is why Denner will probably get the share price up, before making a deal.
KIWI ...Could Kaiser have submitted the Mitigate study results to the ACC in N.O. on march 4 through 6 as a late breaking study?
A 14 member BOD is too unwieldy, especially for a small company...I predict Denner will cut it down to make it more effective...perhaps retaining 2 or 3 from the former board.
sts...You leave the U.S. out of the equation and also assume that Amarin won't be sold by 2024.
Market conditions should be improving before 2024 and the company will be for sale IMO.
KM has been CEO for only one and half years...He came at a time of turmoil when Erikson(who did more damage to Amarin than anyone, was stepping down as COB and PWO, who was picked by Erikson, was just getting acquainted with the job.(KM had been SVP for Europe for about a year before his becoming CEO)...IMO he is not responsible for the fall in share price after he took over as CEO and not responsible for the proxy war, which I believe was orchestrated by PWO.
Seeing whether KM is on board with his plans will be Denners first priority.
I interpreted the "diversified cardiometabolic play" to be a statin Vascepa or a statin MND-2119 combo drug...It could be introduced in the U.S. as a patented drug.
Since statins and Vascepa have proven track records in reducing CVD, the combo drug should gain easy approval from the FDA.
The main item that I was hoping that what would be mentioned in the C.C. was....does Amarin have any plans to recapture the American market?...This was not mentioned...I did not really expect any plans for a potential sale of the company to be mentioned and it was not.
These were the two items I was most interested in.
Churchill uttered those lines upon hearing that America was entering the war against the axis powers...He correctly calculated that the superior assets of the allies would gradually overcome their enemies...with Denner on our side, we too can gradually overcome.
Eliquis and Vascepa would make a great combo drug.....Amarin should apply for a patent.
Nike..." Pfizer still manufactures the “little blue pill,”
LR...Pfizer has an interest in Vascepa and has enough cash to make the deal... and, more importantly, to develop EPA products around the world...Also PFE has several patents expiring in the near future.
I take Eliquis and Vascepa daily...If it turns out to be a stock deal, I would definitely hold my Pfizer shares long term.
Jim...I hope the sale of Amarin is to a big BP for stock instead of cash...I will keep holding that stock of the acquiring company and I will be watching for EPA products attain the market that they deserved, but failed to attain with Amarin.
Tatsu...The new COB will determine that.
That would have to come from Amarin and they would not do it unless they won...No news is good news.
bid...I think "up to" really means 'up yours'
In the HLS agreement..."Terms of the agreement include up-front and milestone payments to Amarin of up to US$65.0 million. These payments include a non-refundable upfront payment of US$5.0 million, which Amarin received when the agreement was reached, as well as development, regulatory and sale-based milestones totaling up to an additional US$60.0 million. The agreement also provides for HLS to pay Amarin tiered double digit royalties on net sales of VASCEPA in Canada. "
I am speculating that this latest agreement includes an up front agreement of only about $1million and that's why Amarin isn't telling us....since it represents only a fraction of what they spent on the proxy fight.
Raf ...The amount of the 'up front payment' was left vague.
" Amarin will receive an upfront payment and be eligible for event-related milestone payments of up to approximately $8 million and additional product-related milestone payments of up to approximately $4 million Amarin will receive an upfront payment and be eligible for event-related milestone payments of up to approximately $8 million and additional product-related milestone payments of up to approximately $4 million"...We are left to guess how much the up front payment was....We also don't know the meaning of...'additional product related milestone payments'....?MND-2119?...
Amarin has a practice of leaving shareholders out of the loop.
You're correct...the Nasdaq site mistakenly referred to the day volume as the after- hours volume.
Approximately 2 million Amarin shares have traded after hours with no significant movement in price.
What is the downside for PWO in a proxy fight loss?...He wont suffer much financially...He is already relatively wealthy and doesn't have that many shares of Amarin anyway....His main downside is reputational...He has made promises to board members, especially the ones that he recently appointed, and he doesn't want to look bad to them and to the world.
In PWO 's case,the future of Amarin is secondary to his good reputation...If Sarissa wins the proxy battle and turns Amarin's current low share price around...either by a commercial success or by a sale, it would make PWO look even worse in hindsight.
PWO does not really consider the plight of the shareholders as HIS problem...thus the unjustifiable recent rewards to the board
and his hateful contempt for Denner.
This recent stock heist. IMO, amounts to embezzlement of shareholder equity.
It was one thing for Amarin to dilute at $18/share...It would be a totally different situation, and a totally unacceptable one, for Amarin to dilute further at $2/sh... mainly in order to continue paying management their salaries, which are on the generous side for a small company with one drug.
Amarin needs to be SOLD...not to be bled dry....EPA is a great drug...get it in the hands of a great BP!
GIA was a feasible idea before Du...NOT after Du...Management seems not to have recognized this.